Đang chuẩn bị liên kết để tải về tài liệu:
Homologous recombination proficiency in ovarian and breast cancer patients

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Homologous recombination and DNA repair are important for genome maintenance. Genetic variations in essential homologous recombination genes, including BRCA1 and BRCA2 results in homologous recombination deficiency (HRD) and can be a target for therapeutic strategies including poly (ADP-ribose) polymerase inhibitors (PARPi). |

TÀI LIỆU LIÊN QUAN

Landscape of homologous recombination deficiencies in solid tumours: Analyses of two independent genomic datasets

Mechanism of Eukaryotic Homologous Recombination

Lecture Molecular biology: Chapter 22 - Robert F. Weaver

Lecture Molecular biology (Fifth Edition): Chapter 22 - Robert F. Weaver

Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors

CoreSimul: A forward-in-time simulator of genome evolution for prokaryotes modeling homologous recombination

Stimulation of homologous recombination in plants expressing heterologous recombinases

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort